Komori
Terumo (4543) · InitiativeRestated

Sale of Shares in Olympus Terumo Biomaterials

First written in FY2024-Q1. 1 of 3 entries say "Achieved", first in FY2024-Q1. Latest entry: FY2024-Q3.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAchievedFY2024-Q1 – FY2024-Q22023: 220232024: 12024
Same theme, other companies
Removal from Equity-Method Accounting Due to the Transfer of All Shares in an AssociateA theme 81 companies write about · 2 as a headwind · 22 as a tailwind

The whole theme swung hardest in 2026: 1 of 8 companies on the "Worse" side.

20 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 81 companies compared. The sentences above are computed from all 81.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3RestatedAnnual report

    「Temporary profit of ¥463 million includes a ¥1,335 million gain on the sale of shares in an affiliate arising from the sale of shares in オリンパステルモバイオマテリアル株式会社, ¥1,125 million in business restructuring expenses, and other items.」

    The ¥1,335 million gain on sale arising from completion of the sale of shares in オリンパステルモバイオマテリアル was also confirmed as temporary profit for the cumulative FY2024-Q3 period.
  2. FY2024-Q2AdvancedAnnual report

    「Temporary profit of ¥585 million includes a ¥1,335 million gain on the sale of shares in an affiliate arising from the sale of shares in オリンパステルモバイオマテリアル株式会社 and ¥750 million in business restructuring expenses.」

    Following completion of the sale of shares in オリンパステルモバイオマテリアル, it was confirmed that a gain on sale of ¥1,335 million had been recorded in profit for the cumulative FY2024-Q2 period.
  3. FY2024-Q1AchievedAnnual report

    「The Company and OLYMPUS CORPORATION agreed on 24 July 2023 to sell all shares in オリンパステルモバイオマテリアル株式会社 held by the Company, an equity-method affiliate, to the Olympus Group. The sale was completed on 4 August 2023, and the Company expects to record a gain on sale of ¥1,335 million as "Other income" in the condensed quarterly consolidated income statement for the second quarter.」

    The Company agreed on 24 July 2023 to sell all shares held in its equity-method affiliate オリンパステルモバイオマテリアル and completed the sale on 4 August. It disclosed that it expected to record a gain on sale of ¥1,335 million in the second quarter.
Moved together

"Growth in the Blood Systems business centered on apheresis, cell processing and emerging markets" moved the same way as this thread, in the same document, in 2 of its 3 moves.

222222★123456
  1. ★This thread
  2. 1Growth in the Blood Systems business centered on apheresis, cell processing and emerging markets2×
  3. 2Expanding market share in global markets and enhancing brand value2×
  4. 3Global sales expansion of cardiovascular products such as Ultimaster2×
  5. 4Strengthening Cost Competitiveness Through Products Tailored to Regional Needs and a Global Production Network2×
  6. 5Consistent Dividend Growth and a Medium- to Long-Term Payout Ratio of 30%2×
  7. 6Reinvestment of Retained Earnings in Research and Development, Production Facilities and Overseas Expansion2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Terumo yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Sale of Shares in Olympus Terumo Biomaterials | TERUMO CORPORATION (4543) | Komori